Agios Pharmaceuticals (AGIO) has opened Q1 2026 earnings season with a recent run of quarterly results that show total revenue of $19.97 million in Q4 2025 and a basic EPS loss of $1.85, alongside trailing twelve month revenue of $54.03 million and a basic EPS loss of $7.12. Over the past six reported quarters, the company has seen quarterly revenue move between $8.73 million and $19.97 million, while basic EPS has ranged from a loss of $1.55 to a one off positive print of $16.65, giving investors a wide spread of outcomes to weigh. Taken together, the latest numbers put the focus squarely on how efficiently Agios is converting that top line into sustainable margins.

See our full analysis for Agios Pharmaceuticals.

With the headline figures in place, the next step is to see how these results line up against the widely held narratives around Agios's growth story, risk profile, and long term earnings potential.

Revenue base grows, but losses stay heavy

• Over the last six reported quarters, total revenue moved from US$8.73 million to US$19.97 million, while net income over the latest trailing twelve months was a loss of US$412.78 million, which ties back to a trailing EPS loss of US$7.12.
• Bulls highlight that revenue is forecast to grow about 37.8% per year and see that as the core of the story, yet the recent trailing loss of US$412.78 million keeps the bullish case heavily dependent on future execution rather than current profitability.
  • On the positive side, bullish arguments point to strong top line momentum and potential for PYRUKYND and the broader rare disease pipeline to build multiple revenue streams on top of the current US$54.03 million trailing revenue base.
  • At the same time, the series of quarterly losses between roughly US$89 million and US$112 million over 2024 and 2025 shows that, so far, higher revenue has not translated into earnings, which is an important caveat for the bullish narrative.

Analysts who are upbeat on Agios often argue that strong revenue growth can eventually reshape the story, but the size of current losses makes it important to see how that thesis is supposed to play out in detail before getting too carried away. 🐂 Agios Pharmaceuticals Bull Case

Valuation signals pull in opposite directions

• At a share price of US$28.05, Agios is described as trading about 84.7% below an indicated DCF fair value of roughly US$183.83, yet its P/S of 30.4x is far above peers at 5.2x and the US Biotechs average of 10.8x.
• Bears focus on this tension, arguing that paying a much higher P/S multiple than peers for a company that is still loss making, with no forecast path to profitability in the next three years, makes the DCF upside harder to rely on.
  • The high P/S multiple sits on top of just US$54.03 million in trailing revenue and a trailing EPS loss of US$7.12, which critics see as a lot of optimism embedded into each dollar of current sales.
  • At the same time, the reference analyst price target of US$41.13 is well below the DCF fair value figure. This suggests that even forward looking models are not aligned on how to interpret the present valuation gap.

Skeptical investors often focus on this mix of a rich sales multiple, deep current losses and wide model dispersion, and use it as a reason to study the cautious case in more detail before committing fresh capital. 🐻 Agios Pharmaceuticals Bear Case

Growth forecasts meet persistent unprofitability

• Losses have been shrinking at about 32.8% per year over the past five years according to the analysis, yet Agios is still expected to remain unprofitable for at least the next three years, even with revenue growth forecast at around 37.8% per year.
• The consensus narrative balances these two ideas, suggesting that new indications and international partnerships could build several long term revenue streams, while also stressing that the current focus on PYRUKYND, high R&D and SG&A spending, and safety and regulatory risks leave earnings heavily exposed.
  • On one side, the growth view points to upcoming U.S. and ex U.S. opportunities around rare hematology. If they materialize, they would be building on a relatively small trailing revenue base of US$54.03 million.
  • On the other, the record of quarterly net losses between roughly US$89 million and US$112 million and the absence of near term profitability guidance show why analysts still frame this as a long duration story rather than a near term earnings play.

Next Steps

To see how these results tie into long-term growth, risks, and valuation, check out the full range of community narratives for Agios Pharmaceuticals on Simply Wall St. Add the company to your watchlist or portfolio so you'll be alerted when the story evolves.

Given the mix of optimism and caution running through these numbers, it makes sense to move quickly, review the details for yourself, and decide where you stand by weighing the 2 key rewards and 1 important warning sign.

See What Else Is Out There

Agios combines a P/S of 30.4x with trailing twelve month revenue of just US$54.03 million and a loss of US$412.78 million, which keeps risk high.

If you want ideas where pricing lines up more closely with earnings power and balance sheet strength, check out the 71 resilient stocks with low risk scores today while conditions still look favorable.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.